Wednesday, July 8, 2026

pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL

COLLEGIUM PHARMACEUTICAL

COLLEGIUM PHARMACEUTICAL clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
Status
Public
HQ
100 Technology Center Dr, Stoughton, Massachusetts 02072, US
Employees
617
Programs
29
Drugs
48
Patents
28
Intelligence · Clinical Programs

COLLEGIUM PHARMACEUTICAL projects

17 ClinicalTrials.gov programs sponsored by COLLEGIUM PHARMACEUTICAL.

COLLEGIUM PHARMACEUTICAL has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AERD-COV19

    COLLEGIUM PHARMACEUTICAL, INC

    aspirin-exacerbated respiratory disease

    phase 3 small molecule active

    1 trial
  2. CADET-PAD

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial
  3. DICES

    COLLEGIUM PHARMACEUTICAL, INC

    Breast cancer

    phase 3 other active

    1 trial
  4. De-escalation to ticagrelor 60 mg at day 30

    COLLEGIUM PHARMACEUTICAL, INC

    Non ST Segment Elevation Acute Coronary Syndrome

    phase 3 small molecule active

    1 trial
  5. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial
  6. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial
  7. Evolocumab

    COLLEGIUM PHARMACEUTICAL, INC

    Sars-CoV-2 Infection

    phase 3 small molecule completed

    1 trial
  8. HLD200 methylphenidate hydrochloride capsules

    COLLEGIUM PHARMACEUTICAL, INC

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial
  9. HYP-NOR

    COLLEGIUM PHARMACEUTICAL, INC

    hypotension in non-cardiac surgery

    phase 3 small molecule active

    1 trial
  10. IRINOTECAN

    COLLEGIUM PHARMACEUTICAL, INC

    Gastric Carcinoma

    phase 3 small molecule active

    1 trial
  11. Methoxyflurane - Penthrox

    COLLEGIUM PHARMACEUTICAL, INC

    ST Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial
  12. Oxycodone DETERx

    COLLEGIUM PHARMACEUTICAL, INC

    Chronic Low Back Pain

    phase 3 small molecule completed

    1 trial
  13. PB_A&A-ASC-FISTULA_1

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial
  14. PREVENT-MINS

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Injury after Noncardiac Surgery

    phase 3 small molecule active

    1 trial
  15. Qarziba 4.5 mg/mL concentrate for solution for infusion

    COLLEGIUM PHARMACEUTICAL, INC

    Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment.

    phase 3 small molecule active

    1 trial
  16. Ticagrelor 90 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial
  17. Ticagrelor 90mg

    COLLEGIUM PHARMACEUTICAL, INC

    STEMI

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does COLLEGIUM PHARMACEUTICAL have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.